Oncopeptides AB (LTS:0RN4) E10: kr-6.62 (As of Mar. 2026)


LTS:0RN4 Oncopeptides AB LTS:0RN4
46 GF Score
Price kr1.66
GF Value kr4.23
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Oncopeptides AB E10?

Oncopeptides AB LTS:0RN4 -0.96% 46 E10 is kr-6.62 as of Mar. 2026. GuruFocus rates LTS:0RN4 with a GF Score™ of 46/100 and a GF Value™ of kr4.23 (Possible Value Trap). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Oncopeptides AB's adjusted earnings per share data for the three months ended in Mar. 2026 was kr-0.120. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is kr-6.62 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-07), Oncopeptides AB's current stock price is kr1.6565. Oncopeptides AB's E10 for the quarter that ended in Mar. 2026 was kr-6.62. Oncopeptides AB's Shiller PE Ratio of today is .


Oncopeptides AB  (LTS:0RN4) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Oncopeptides AB E10 Related Terms


Oncopeptides AB E10 Historical Data

* Premium members only.

The historical data trend for Oncopeptides AB's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncopeptides AB E10 Chart

Oncopeptides AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -7.11

Oncopeptides AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -7.02 -7.11 -6.62

LTS:0RN4 vs VRTX, REGN, ALNY: E10 Comparison

For the Biotechnology subindustry, Oncopeptides AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncopeptides AB Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncopeptides AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Oncopeptides AB's Shiller PE Ratio falls into.


LTS:0RN4
46GF Score
Oncopeptides AB LTS:0RN4
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncopeptides AB E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Oncopeptides AB's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.12/133.5600*133.5600
=-0.120

Current CPI (Mar. 2026) = 133.5600.

Oncopeptides AB Quarterly Data

per share eps CPI Adj_EPS
201606 -0.383 101.019 -0.506
201609 -0.403 101.138 -0.532
201612 -1.013 102.022 -1.326
201703 -1.198 102.022 -1.568
201706 -1.071 102.752 -1.392
201709 -0.824 103.279 -1.066
201712 -1.052 103.793 -1.354
201803 -0.989 103.962 -1.271
201806 -2.092 104.875 -2.664
201809 -1.356 105.679 -1.714
201812 -1.616 105.912 -2.038
201903 -0.018 105.886 -0.023
201906 -2.231 106.742 -2.792
201909 -2.237 107.214 -2.787
201912 -2.808 107.766 -3.480
202003 -3.404 106.563 -4.266
202006 -4.304 107.498 -5.347
202009 -3.619 107.635 -4.491
202012 -4.881 108.296 -6.020
202103 -2.187 108.360 -2.696
202106 -0.203 108.928 -0.249
202109 -6.548 110.338 -7.926
202112 -2.998 112.486 -3.560
202203 -0.830 114.825 -0.965
202206 -0.501 118.384 -0.565
202209 -0.634 122.296 -0.692
202212 -0.640 126.365 -0.676
202303 -0.501 127.042 -0.527
202306 -0.551 129.407 -0.569
202309 -0.400 130.224 -0.410
202312 -0.800 131.912 -0.810
202403 -0.667 132.205 -0.674
202406 -0.427 132.716 -0.430
202409 -0.274 132.304 -0.277
202412 -0.368 132.987 -0.370
202503 -0.290 132.825 -0.292
202506 -0.267 133.699 -0.267
202509 -0.255 133.480 -0.255
202512 -0.236 133.390 -0.236
202603 -0.120 133.560 -0.120

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of kr-6.62 mean?
Oncopeptides AB (LTS:0RN4) has a E10 of kr-6.62 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Oncopeptides AB and its competitors.
Is Oncopeptides AB's E10 too high?
Oncopeptides AB's current E10 is kr-6.62. Overall, Oncopeptides AB has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncopeptides AB's E10 compare to VRTX and REGN?
Oncopeptides AB's E10 of kr-6.62 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Oncopeptides AB and its competitors. Oncopeptides AB's current E10 is kr-6.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncopeptides AB stock overvalued right now?
Based on GuruFocus' analysis, Oncopeptides AB (LTS:0RN4) is currently considered Possible Value Trap. The stock's GF Value™ is kr4.23, compared to a current price of kr1.66 — trading 60.8% below its estimated fair value. The current E10 is kr-6.62. Oncopeptides AB's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Oncopeptides AB (LTS:0RN4), the current E10 is kr-6.62 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncopeptides AB (LTS:0RN4) Overvalued in 2026?

Based on GuruFocus' analysis, Oncopeptides AB stock appears to be undervalued. The current stock price of kr1.66 is trading 60.8% below its estimated GF Value™ of kr4.23. GuruFocus considers Oncopeptides AB to be Possible Value Trap.

Key valuation signals for LTS:0RN4:

  • E10: kr-6.62
  • GF Value™: kr4.23 vs. price of kr1.66 (60.8% below fair value)
  • GF Score™: 46/100 with 3 warning signs

No single metric tells the full story. See the LTS:0RN4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Oncopeptides AB Business Description

Address Luntmakargatan 46, Stockholm, SWE, SE-111 37
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.
46GF Score

Get the complete analysis for LTS:0RN4

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.66
Price
kr4.23
GF Value